Real world experience of nivolumab therapy in metastatic renal cancer patients: A 3 year multi-centre review

Background null In the UK renal cancer has an incidence of around 12600 cases per year. Nivolumab is an anti-PD1 checkpoint inhibitor, which was approved in the UK for second or subsequent line treatment of advanced renal cancer in 2016. The aim of this study was to evaluate a regional experience of nivolumab use in this setting. null null null Methods null A retrospective analysis was undertaken of patients who commenced nivolumab as...